Drug Profile
VML 530
Alternative Names: ABT 080Latest Information Update: 04 Feb 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer Vernalis Group
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action 5-lipoxygenase activating protein inhibitors; Leukotriene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma